Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation

(2015) Carolina Simioni et al.   Oncotarget

Reduction of HIV Persistence Following Transplantation in HIV-Infected Kidney Transplant Recipients

(2014) P. G. Stock et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations

(2014) M Moschetta et al.   BRITISH JOURNAL OF PHARMACOLOGY

Antiretroviral Treatment of Adult HIV Infection

(2014) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer

(2014) Venkatasubbaiah A Venkatesha et al.   Molecular Cancer

MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma

(2014) E. K. Slotkin et al.   MOLECULAR CANCER THERAPEUTICS

The HIV pipeline

(2014) Angel Wong   NATURE REVIEWS DRUG DISCOVERY

Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models

(2014) Giovanni Luca Gravina et al.   PROSTATE

Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood-Brain Barrier without restriction by ABCB1 and ABCG2

(2013) Fan Lin et al.   INTERNATIONAL JOURNAL OF CANCER

Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)

(2013) Craig S. Takeuchi et al.   JOURNAL OF MEDICINAL CHEMISTRY

The end of AIDS: HIV infection as a chronic disease

(2013) Steven G Deeks et al.   LANCET

Rapamycin-induced modulation of HIV gene transcription attenuates progression of HIVAN

(2012) Partab Rai et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Dynamic roles for NF-κB in HTLV-I and HIV-1 retroviral pathogenesis

(2012) Jonathan K. Chan et al.   IMMUNOLOGICAL REVIEWS

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

(2012) M R Janes et al.   LEUKEMIA

The translational landscape of mTOR signalling steers cancer initiation and metastasis

(2012) Andrew C. Hsieh et al.   NATURE

New generation humanized mice for virus research: Comparative aspects and future prospects

(2012) Ramesh Akkina   VIROLOGY

Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors

(2011) J. K. Altman et al.   CLINICAL CANCER RESEARCH

Human immunodeficiency virus-1 Tat activates NF-κB via physical interaction with IκB-α and p65

(2011) Giuseppe Fiume et al.   NUCLEIC ACIDS RESEARCH

A Versatile Role of Mammalian Target of Rapamycin in Human Dendritic Cell Function and Differentiation

(2010) M. Haidinger et al.   JOURNAL OF IMMUNOLOGY

HIV-1 Tat and Host AFF4 Recruit Two Transcription Elongation Factors into a Bifunctional Complex for Coordinated Activation of HIV-1 Transcription

(2010) Nanhai He et al.   MOLECULAR CELL

HIV-1 Tat Assembles a Multifunctional Transcription Elongation Complex and Stably Associates with the 7SK snRNP

(2010) Bijan Sobhian et al.   MOLECULAR CELL

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Potent Activity of a Nucleoside Reverse Transcriptase Inhibitor, 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine, against Human Immunodeficiency Virus Type 1 Infection in a Model Using Human Peripheral Blood Mononuclear Cell-Transplanted NOD/SCID Janus Kinase 3 Knockout Mice

(2009) S. Hattori et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

(2009) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

(2009) K. Yu et al.   CANCER RESEARCH

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

(2009) Erika L. Pearce et al.   NATURE

mTOR regulates memory CD8 T-cell differentiation

(2009) Koichi Araki et al.   NATURE

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

Global Analysis of Host-Pathogen Interactions that Regulate Early-Stage HIV-1 Replication

(2008) Renate König et al.   CELL

Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin

(2008) F. Nicoletti et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling

(2008) Tsuneo Ikenoue et al.   EMBO JOURNAL

The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C

(2008) Valeria Facchinetti et al.   EMBO JOURNAL

Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1

(2008) A. Heredia et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA